Recently, antimicrobial therapy with newer agents such as ceftazidime-avibactam, cefiderocol and meropenem-vaborbactam offer promising alternatives to existing agents for the treatment of severe infections due to KPC-Kp. The gene discussed is NPPA; the disease is infection.